Login to Your Account



Seeking to be a Global Rare Disease Company

Synageva Kicks into High Gear with its $156M Public Offering

By Jennifer Boggs
Managing Editor

Wednesday, September 25, 2013
financings_resized.jpg

In its fourth substantial public offering in two years, Synageva Biopharma Corp. padded its balance sheet with a $155.7 million to accelerate its aspirations of becoming a global rare disease company replete with burgeoning pipeline programs, manufacturing and commercial infrastructure.

That’s a plan investors appear to be endorsing wholeheartedly, no doubt fueled by growing enthusiasm for the rare disease space, as evidenced by rampant buyout speculation involving Alexion Pharmaceuticals Inc. and Biomarin Pharmaceutical Inc. (See BioWorld Today, Sept. 20, 2013.)

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription